Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Idioma: | |
| Publicado em: |
Zenodo
2025
|
| Assuntos: | |
| Acesso em linha: | https://doi.org/10.5281/zenodo.14982871 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
Sumário:
- <p><span>The gut microbiome, a diverse community of microorganisms, plays a crucial role in immune regulation and the development of autoimmune diseases, including autoimmune arthritis (AA). Dysbiosis, or microbial imbalance, has been linked to the onset and progression of conditions like rheumatoid arthritis (RA) and psoriatic arthritis (PsA). Alterations in the gut microbiota composition can lead to immune system dysfunction, promoting inflammation and joint damage. In autoimmune arthritis, dysbiosis can result in increased production of pro-inflammatory cytokines and autoantibodies, contributing to joint inflammation. Additionally, the disruption of intestinal permeability allows microbial products to enter the bloodstream, triggering systemic immune responses. Certain microbial species, such as Prevotella and Bacteroides, are associated with pro-inflammatory effects, while Lactobacillus and Bifidobacterium may exert anti-inflammatory properties that could help mitigate symptoms. Microbiome-based therapies, including probiotics, prebiotics, and fecal microbiota transplantation (FMT), show promise in modulating immune responses and alleviating autoimmune arthritis symptoms. However, while preclinical studies demonstrate potential, clinical evidence remains limited, and more research is needed to explore these interventions</span><span>. </span></p>